BIO-SENSING SOLUTIONS SL

Their core work

BIO-SENSING SOLUTIONS SL (trading as DYCARE) is a Barcelona-based health technology SME that develops digital tools for clinical assessment and rehabilitation of musculoskeletal and neurological conditions. Their core work is translating biosensing data — motion, movement quality, physical performance — into clinically meaningful recovery metrics. Their flagship product, ReHub, is a digital recovery therapy platform designed to guide and monitor patients through rehabilitation remotely. They operate at the intersection of wearable sensing, digital therapeutics, and clinical outcomes measurement.

What they specialise in

How they've shifted over time

DYCARE began in 2016 with a Phase 1 feasibility study focused on clinical assessment tooling — a broad proof-of-concept covering both musculoskeletal and neurological domains. By 2018 they had sharpened their focus to a single commercial product: ReHub, a digital recovery therapy platform, which secured a Phase 2 grant more than twenty times larger than the Phase 1 award. The trajectory is unambiguous: from research-grade assessment tools toward a scalable, deployable digital therapeutics product ready for European market entry.

DYCARE is moving from clinical instrumentation toward a software-as-a-service or digital therapeutics product model, positioning ReHub as a scalable commercial platform rather than a research device — making them a candidate partner for healthcare providers, insurers, or med-tech integrators rather than research consortia.

How they like to work

DYCARE has acted as sole coordinator on both H2020 projects and recorded zero consortium partners — a pattern typical of SME Instrument grants, which are designed for single-company innovation rather than collaborative research. This means DYCARE has no demonstrated history of working in multi-partner EU consortia. Potential collaborators should expect to approach them as a technology provider or commercial partner rather than a co-applicant with consortium management experience.

DYCARE's H2020 record shows no multi-organization partnerships — both grants were solo applications through the SME Instrument. Their collaboration footprint within EU-funded research is effectively zero, limited entirely to their own company boundary.

What sets them apart

DYCARE is one of the few Spanish health-tech SMEs that successfully progressed from SME Instrument Phase 1 to Phase 2 within the same technology domain — a strong signal of both product maturity and grant-writing capability. Their claim to have built "The World's first Digital Recovery Therapy solution" with ReHub positions them as a first-mover in a specific niche of remote rehabilitation, not a generic digital health company. For consortium builders in the digital health or medical device space, they offer a commercially validated product and a regulatory-aware development track record, rather than early-stage research.

Highlights from their portfolio

• ReHub
  A EUR 1,058,485 SME Instrument Phase 2 award — the most competitive tier of EU SME funding — positioning ReHub as a commercially ready digital therapy platform for post-operative and chronic rehabilitation, claimed by the company as a global first in its category.
• Dycare
  The Phase 1 feasibility project that validated the clinical and commercial concept underpinning the company's entire product line, covering both musculoskeletal and neurological disorder assessment in a single scope.